COMMUNIQUÉS West-GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results
27/02/2019
—Roxadustat Approved in China for Anemia in Dialysis-Dependent CKD Patients — —Primary Efficacy Endpoints Met in Seven Phase 3 Roxadustat Studies for U.S./EU— —Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. [...]
CytomX Therapeutics Announces Full-Year 2018 Financial Results
27/02/2019
Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage [...]
Rafina Innovations Inc Comments on Recent Stock Volume and Price Increase
27/02/2019
GLASGOW, SCOTLAND, Feb. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Rafina Innovations Inc has been advised of a significant increase in the share price and trading volume of the Company's shares beginning Monday [...]
Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
27/02/2019
REDWOOD CITY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), [...]
Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results
27/02/2019
BERKELEY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an important year for Aduro [...]
OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results
27/02/2019
Conference Call begins today at 4:30 p.m. Eastern Time MIAMI, Feb. 27, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, [...]
SeaSpine Announces Fourth Quarter and Full-Year 2018 Results and Reaffirms 2019 Revenue Guidance
27/02/2019
CARLSBAD, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]
Imagin Medical Reports Fiscal 2019 First Quarter Results
27/02/2019
VANCOUVER, British Columbia and BOSTON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results [...]
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results
27/02/2019
Pre-NDA Meeting Completed and Company Announces FDA Agreed to a Rolling Submission of New Drug Application for Voxelotor for the Potential Treatment of Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 ( [...]
Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
27/02/2019
RNA Franchise Advances -Reported EXONDYS 51® (eteplirsen) net sales of $84.4M for the quarter and full-year net sales of $301.0M, in line with guidance- -Filed NDA for golodirsen with priority review, PDUFA August 19 th [...]
Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
27/02/2019
-- NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI -- -- New England Journal of Medicine Publishes Results from Two Pivotal Phase 3 Studies of NUZYRA -- -- Company Executes [...]
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update
27/02/2019
BURNABY, British Columbia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2018 financial and operating [...]
Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
27/02/2019
Xtampza ® ER Prescriptions Grew 233% in 2018 Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full Year Cash and Cash Equivalents were $146.6 million as of December 31, 2018, [...]
FDA Grants T2 Biosystems Breakthrough Device Designation for the T2Resistance™ Panel; Expected Availability through CE Mark in 2019
27/02/2019
New, expanded panel detects gram-negative and gram-positive resistance genes to help combat antimicrobial resistant bloodstream infections LEXINGTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- The FDA has granted T2 [...]
Teladoc Health Reports Fourth-Quarter and Full-Year 2018 Results
27/02/2019
Fourth-quarter revenue grows 59% to $122.7 million; Full-year 2018 revenue grows 79% to $417.9 million Fourth-quarter total visits up 86% to 861,000; 2018 total visits up 80% to 2.6 million Issues Initial 2019 Guidance [...]
NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
27/02/2019
Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa, Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and [...]
aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation
27/02/2019
Poster presentation at the Keystone Symposia 2019 Conference: Myeloid Cells (B7) SAN DIEGO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and [...]
GENFIT: PUBLICATION OF THE 2018 REGISTRATION DOCUMENT
27/02/2019
GENFIT: PUBLICATION OF THE 2018 REGISTRATION DOCUMENT Lille (France), Cambridge (Massachusetts, United States), February 27, 2019 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a late-stage biopharmaceutical company [...]
GENFIT : MISE À DISPOSITION DU DOCUMENT DE RÉFÉRENCE 2018
27/02/2019
GENFIT : MISE À DISPOSITION DU DOCUMENT DE RÉFÉRENCE 2018 Lille (France), Cambridge (Massachusetts, États-Unis), le 27 février 2019 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), Société biopharmaceutique de phase [...]

Pages